Valuation : Coya Therapeutics, Inc.

Market Cap 108M 93.05M 87.62M 79.83M 149M 10.29B 150M 1.04B 401M 5.24B 406M 397M 16.61B P/E 2026 *
-3.48x
P/E 2027 * -3.22x
Enterprise Value 108M 93.05M 87.62M 79.83M 149M 10.29B 150M 1.04B 401M 5.24B 406M 397M 16.61B EV / Sales 2026 *
106x
EV / Sales 2027 * 21.8x
Free-Float
83.27%
Yield 2026 *
-
Yield 2027 * -
09-08 Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of Coya 303 in A Well-Established Model of Peripheral and Cns Inflammation CI
08-11 Coya Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-07 Coya Therapeutics, Inc. Appoints Mark H. Pavao to Its Audit Committee of Board, Effective August 7, 2026 CI
06-18 Coya Therapeutics Presents Alstars Trial Design At Encals 2026 Meeting CI
06-08 Coya Therapeutics Says Phase 2 ALS Study Enters Blinded Extension Phase MT
06-08 Coya Therapeutics, Inc. Initiates Blinded Extension Phase of ALSTARS Trial CI
06-05 Roth Capital Initiates Coverage on Coya Therapeutics With Buy Rating, $12 Price Target MT
05-27 Coya Therapeutics Presents ALSTARS Trial Design And Provides Update On COYA 302 For ALS CI
05-12 Coya Therapeutics entered into sales agreement, may offer and sell from time to time shares of co's common stock for up to $30 million RE
05-12 Coya Therapeutics has been granted U.S. FDA fast track designation for Coya 302 for the treatment of amyotrophic lateral sclerosis (ALS) RE
05-12 Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-12 Coya Therapeutics, Inc. Is Receives FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis CI
04-09 Coya Therapeutics, Inc. Publishes Study Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting Mechanistic Rationale for Coya 302 in Patients with Als CI
1 week+4.30%
Current month+1.10%
1 month-4.16%
3 months+2.90%
6 months-4.75%
Current year-20.52%
1 week 4.52
Extreme 4.52
4.82
1 month 4.36
Extreme 4.36
5.26
Current year 3.71
Extreme 3.7101
6.21
1 year 3.71
Extreme 3.7101
7.75
3 years 3.21
Extreme 3.21
10.69
5 years 3.21
Extreme 3.21
10.69
10 years 3.21
Extreme 3.21
10.69
Manager TitleAgeSince
Chief Executive Officer 57 2024-10-31
President 67 2023-07-16
Director of Finance/CFO 65 2022-03-29
Director TitleAgeSince
Director/Board Member 58 2021-02-28
Director/Board Member 67 2021-05-24
Director/Board Member 64 2021-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/26 Free

Director

10,000 0.0426%
1/22/26 Free

Chief Financial Officer

140,041 0.6693%
1/22/26 Free

Chief Executive Officer

15,257 0.0729%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+4.30%-26.48%-7.62% 108M
-3.24%-7.78%-5.35%+11.20% 48.01B
+0.17%-0.74%+407.28%+546.58% 44.44B
-0.86%-2.60%+35.51%+20.35% 42.67B
-0.14%-2.98%-0.04%+82.21% 39.96B
0.00%-1.72%+13.42%+42.33% 32.75B
-3.44%-2.43% - - 17.74B
-0.78%-1.13%+20.74%+116.26% 16.49B
-0.37%-2.53%+10.91%+30.93% 14.38B
-0.86%-4.60%+76.86%+39.36% 13.4B
Average -0.95%-1.52%+59.21%+97.96% 26.99B
Weighted average by Cap. -1.04%-2.20%+84.54%+131.86%

Financials

2026 *2027 *
Net sales 1.02M 876K 825K 752K 1.41M 96.92M 1.41M 9.78M 3.78M 49.38M 3.82M 3.74M 156M 4.96M 4.27M 4.02M 3.66M 6.85M 472M 6.88M 47.65M 18.42M 241M 18.63M 18.23M 762M
Net income -30.48M -26.23M -24.69M -22.5M -42.1M -2.9B -42.27M -293M -113M -1.48B -114M -112M -4.68B -33.18M -28.55M -26.88M -24.5M -45.83M -3.16B -46.01M -319M -123M -1.61B -125M -122M -5.1B
Net Debt - -
Logo Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.
Employees
8
Date Price Change Volume
26-09-09 US$4.610 0.00% 77,817
26-09-08 US$4.610 -3.15% 98,353
26-09-04 US$4.760 +4.62% 75,759
26-09-03 US$4.550 +2.94% 100,315
26-09-02 US$4.420 -2.00% 61,902
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.610USD
Average target price
15.21USD
Spread / Average Target
+230.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COYA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!